Thursday, April 3, 2014
Genmab A/S and Utrecht University researchers have
shown that hexameric IgG complexes can activate the complement cascade,
providing the molecular rationale behind the biotech's HexaBody platform.1
Genmab is now selecting key mutations and antibody candidates to generate IgG
antibodies that potently induce complement-dependent cytotoxicity in cancer and
an insufficient response
key goal of Genmab's HexaBody technology is to provide a general approach for
enhancing the potency of new or existing mAbs without significantly disrupting
their native structure and specificity.
Lou, K.-J. SciBX 7(13); doi:10.1038/scibx.2014.363
Published online April 3, 2014
1. Diebolder, C.A. et al. Science; published online March 13, 2014;
doi:10.1126/science.1248943 Contact: Paul W.H.I.
Parren, Genmab A/S, Utrecht, the Netherlands e-mail: firstname.lastname@example.org Contact: Piet Gros, Utrecht University, Utrecht, the Netherlands
AND INSTITUTIONS MENTIONED
American Society of Hematology, Washington, D.C.
Center of Immunology Pierre Fabre, St. Julien-en-Genevois, France
(CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
The Scripps Research Institute, La Jolla, Calif.
Utrecht University, Utrecht, the Netherlands